Generic Versions of Zantac Recalled Over Cancer Worries

Comments (0)

Drug companies are recalling generic versions of Zantac that were sold at Walgreens, Walmart, and Rite Aid. The drugs are being recalled over concerns that the medicines contain a probable carcinogen. The Walgreens version of the products are called Wal-Zan. The versions sold at Rite Aid and Walmart are called ranitidine tablets. There are several companies that manufacture the drugs. The drugs are used to reduce stomach acid. 

Apotex, one of the companies, is recalling 75 and 150 milligram ranitidine tablets that are sold at the three chain pharmacies, because the drugs may contain low levels of a chemical called NDMA. Sandoz, another manufacturer of the drugs which is owned by Novartis, recalled 30, 50, and 500-count bottles of the capsules. It also announced that it would halt shipment of the drugs. GlaxoSmithKline is also recalling ranitidine pills sold in India and Hong Kong. The company does not sell the drugs in the U.S. 

The recalls occurred after an announcement from the FDA about unacceptable levels of NDMA in Zantac and its generic versions. The FDA is currently testing Zantac but has not yet asked drugmakers to recall the products. NDMA is one of three cancer-causing substances identified in massive recalls of some blood pressure and heart medications.

Unfortunately, many prescription and generic drugs are recalled every year. Some recalls are issued for fairly minor concerns, but others, such as this recall, involve serious concerns. Drug manufacturers have a duty to keep their customers safe. 

If you have been harmed by a prescription drug, you should -speak to an attorney. If you are in Houston, call the Houston drug recall attorneys at Kennedy Hodges at 855-947-0707. We can help. Call us today to learn more or to schedule a free consultation.

Be the first to comment!

Post a Comment

To reply to this message, enter your reply in the box labeled "Message", hit "Post Message."

Name:*

Email:* (will not be published)

Message:*

Notify me of follow-up comments via email.